A curious team of explorers, deeply rooted in science, and constantly on the lookout for a very particular novel drug modality. This is us – Proxygen. We hunt for glue degraders. They are the key to unlocking new treatments for patients. They revolutionize how we see and cure diseases.
Externer Link zu Proxygen
Siemensstraße 89
Vienna, 1210, AT
Use the opportunity to connect with us and find out more about #TheArtOfGlueHunting. Our CEO Bernd Boidol will be in Stockholm next week for the Bio-Europe conference and he can't wait to tell you more about what we do best.
Reach out if you are in Stockholm next week! Looking forward to representing Proxygen at this year's Bio Europe meeting on November 4-6, 2024. #TheArtOfGlueHunting
Proxygen hat dies direkt geteilt
Looking forward to joining the panel on “Lessons Learned from a Major Strategic Partnership Deal for a Platform” at the TPD & Induced Proximity Summit in Boston next week. Join me and trailblazers Barbara Lueckel (Global Head of Research Technologies, Roche), Scott Boyle, Ph.D. MBA (CBO, C4 Therapeutics), and Jason Kantor (CBO, Nurix Therapeutics). #TheArtOfGlueHunting Proxygen
🚨 New Website Alert 🚨 www.proxygen.com 🚨 Proxygen was founded on the belief that significant progress demands boldness and smart differentiation. Instead of aspiring to be 'like' others, we set out to explore uncharted territory, driven by the confidence that our deep scientific roots will guide us in the right direction. This mindset is imperative in a scientific field so groundbreaking and novel like targeted protein degradation. Finding #gluedegraders requires more than just the standard approaches. After all, they represent the paradigm shift in pharmacology that we’ve all been eagerly awaiting. At Proxygen, we do things differently, unconventionally. We combine the art and the skill of hunting for glue degraders. Our new website and visual identity finally reflect this spirit and align perfectly with the cunning science that has defined us from the beginning. Check it out: www.proxygen.com A special shoutout to the outstanding team at Alessandri - Design & Marken Manufaktur, led by the wonderful Cordula Alessandri. The results of your work show just how captivated you were by our story. You truly incorporate the glue hunter spirit.
Collaboration on all levels // Outstanding work by the academic labs of Proxygen co-founder and head of our Scientific Advisory Board Georg Winter and Proxygen SAB member Brenda Schulman - how great to see these two pioneers working together so productively Read the full article: https://lnkd.in/dZ48-fhW
Proxygen hat dies direkt geteilt
Looking forward to participating in Wednesday's panel on "Co-opting Existing Biological Processes to Drug Cancer and Other Diseases" at the BIO International Convention in San Diego. Host Mariana Mihalusova (Venrock) has assembled a brilliant group of pioneers and thought leaders with Drs. Aetna Wun Trombley (CEO Lycia), Larry Hamann (CEO Interdict), and George Eliades (CEO Mythic). Join us for an insightful conversation on Wednesday, June 5 at 4:15 PM. See you there. #BIO2024
Absolutely stunning!! Congratulations to Proxygen co-founder & head of our Scientific Advisory Board Georg Winter and his team for using their deep scientific roots to push the limits of drug discovery once again. Chapeau!!
♨ Hot off the press: We are proud that our chemoproteomics survey is published today in Science Magazine. In brief, proteome-wide profiling of >400 fragments coupled with advanced machine learning tools provides numerous starting points for drug discovery & empowers prediction of ligand behavior in native biological systems. This was a fantastic collaboration with Pfizer scientists led by my fantastic colleague Monica Schenone. In a long list of project champions I want to highlight contributions from Fabian Offensperger, Gary Tin and Miquel Duran-Frigola, Elisa H. and Sarah Dobner [btw: Fabian and Gary just hit the job market]. I also want to thank an expanded team at CeMM that made this work possible in the first place Moreover, I want to mention that this project gave us the chance to continue a scientific trajectory that has been pioneered by Chris Parker during his time in Ben Cravatt’s lab and we are grateful for the inspiration their work has provided. Finally, to maximize the impact of our efforts, all data and predictive models are available via an online resource http://ligand-discovery.ai We hope that this resource will empower and enable many future discoveries. https://lnkd.in/d-vxFeet
Next achievement unlocked +++ Congratulations to Proxygen Co-Founder & Head of our Scientific Advisory Board Georg Winter and all contributing authors for adding yet another piece to the molecular glue degrader puzzle +++
Very happy that our collaboration with Alessio Ciulli (& his fantastic team) on intramolecular bivalent glue degraders as a new modality in targeted protein degradation is out in Nature today. 🎯 🔥 #targetedproteindegradation #TPD #MolecularGlueDegraders CeMM check out the paper below 👇 https://lnkd.in/dHP2sXnH
Publication alert +++ Congratulations to CeMM PI, Proxygen SAB chair and co-founder Georg Winter & colleagues for developing a novel cancer protein killer that forces pathogenic proteins into degradation +++ Read the full story here: https://lnkd.in/g_Rjt4jw
+++ News alert +++ We are honored to welcome Brenda Schulman, Giulio Draetta, Stefan Kubicek, and Georg Winter to our newly formed Scientific Advisory Board. This team of highly regarded thought leaders in the emerging field of protein degradation will offer scientific expertise and guidance to Proxygen as the company works to advance its internal molecular glue degrader programs toward clinical development. +++ Read the full press release here: https://lnkd.in/dNFPB6SM